3 Top-Rated Stocks with Perfect 10 Smart Score and Strong Buy Ratings from Wall Street Analysts

Abbott Laboratories (ABT) has gained 17% YTD and has a Strong Buy rating with an average price target of $144.60, suggesting a 10% upside. Levi Strauss & Co. (LEVI) has gained 23% YTD and has an average price target of $22.70, suggesting a 6.2% upside. BlueLinx Holdings (BXC) has a Strong Buy rating with an average price target of $93.33, suggesting an 11.3% upside despite being down 18% YTD.

In the current quarterly earnings season, Abbott Laboratories (ABT) and Levi Strauss & Co. (LEVI) have shown robust performance, with analysts maintaining positive outlooks and raising price targets. Both companies have demonstrated solid financial health and operational performance, contributing to their strong ratings and potential for further upside.

Abbott Laboratories (ABT)

Abbott Laboratories has seen its stock price gain 17% year-to-date (YTD), with a Strong Buy rating and an average price target of $144.60, suggesting a 10% upside. TD Cowen reiterated its Buy rating and $145.00 price target on the company, citing a strong "GREAT" financial health score [1]. The research firm expects Abbott to meet or exceed Wall Street’s targets for the second quarter, keeping the company on track to achieve its 2025 guidance targets. Abbott has maintained a dividend payment for 55 consecutive years, showcasing its financial stability.

The company has also received FDA approval for its Tendyne transcatheter mitral valve replacement system, enhancing its minimally invasive structural heart therapy portfolio. Oppenheimer and Piper Sandler have maintained their positive ratings on Abbott, highlighting its strategic advancements and ongoing commitment to innovation in healthcare technology.

Levi Strauss & Co. (LEVI)

Levi Strauss & Co. has gained 23% YTD, with an average price target of $22.70, suggesting a 6.2% upside. Wells Fargo, JPMorgan, and Stifel have all raised their price targets for Levi Strauss, reflecting strong earnings and sales growth. The company reported 6% revenue growth in the second quarter, beating Street expectations, and maintained its full-year EBIT margin guidance despite a 20 basis point tariff impact.

Levi Strauss has seen impressive gross profit margins of 60.82% and strong revenue growth of 7.23% over the last twelve months. The company’s performance has been driven by growth across multiple segments, including women’s products, tops, e-commerce, and international sales. Despite challenges in the Asian market, Levi Strauss continues to see strong sales growth in Europe and the United States, driven by its direct-to-consumer business and product innovations.

Conclusion

Both Abbott Laboratories and Levi Strauss & Co. have shown strong earnings and operational performance, with analysts maintaining positive outlooks and raising price targets. Investors should closely monitor these companies' earnings reports and guidance to assess their future prospects. With a 10% and 6.2% upside potential, respectively, both companies present attractive investment opportunities.

References

[1] https://za.investing.com/news/analyst-ratings/abbott-labs-stock-price-target-reiterated-at-145-by-td-cowen-on-strong-outlook-93CH-3786984
[2] https://www.investing.com/news/analyst-ratings/levi-strauss-stock-price-target-raised-to-25-by-wells-fargo-on-strong-q2-93CH-4131655
[3] https://www.investing.com/news/analyst-ratings/levi-strauss-stock-price-target-raised-to-23-from-18-at-jpmorgan-on-strong-earnings-93CH-4131794